Journal Article
. 2006 Feb; 12(3):335-41.
doi: 10.1038/nm1359.

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

Ryan M Teague 1 Blythe D Sather  Jilian A Sacks  Maria Z Huang  Michelle L Dossett  Junko Morimoto  Xiaoxio Tan  Susan E Sutton  Michael P Cooke  Claes Ohlén  Philip D Greenberg  
Affiliations
  • PMID: 16474399
  •     98 citations

Abstract

CD8+ T cells can mediate eradication of established tumors, and strategies to amplify tumor-reactive T-cell numbers by immunization or ex vivo expansion followed by adoptive transfer are currently being explored in individuals with cancer. Generating effective CD8+ T cell-mediated responses to tumors is often impeded by T-cell tolerance to relevant tumor antigens, as most of these antigens are also expressed in normal tissues. We examined whether such tolerant T cells could be rescued and functionally restored for use in therapy of established tumors. We used a transgenic T-cell receptor (TCR) mouse model in which peripheral CD8+ T cells specific for a candidate tumor antigen also expressed in liver are tolerant, failing to proliferate or secrete interleukin (IL)-2 in response to antigen. Molecular and cellular analysis showed that these tolerant T cells expressed the IL-15 receptor alpha chain, and could be induced to proliferate in vitro in response to exogenous IL-15. Such proliferation abrogated tolerance and the rescued cells became effective in treating leukemia. Therefore, high-affinity CD8+ T cells are not necessarily deleted by encounter with self-antigen in the periphery, and can potentially be rescued and expanded for use in tumor immunotherapy.

Adoptive immunotherapy for cancer: building on success.
Luca Gattinoni, Daniel J Powell, Steven A Rosenberg, Nicholas P Restifo.
Nat Rev Immunol, 2006 Apr 20; 6(5). PMID: 16622476    Free PMC article.
Highly Cited. Review.
ITK and IL-15 support two distinct subsets of CD8+ T cells.
Sigrid Dubois, Thomas A Waldmann, Jürgen R Müller.
Proc Natl Acad Sci U S A, 2006 Aug 02; 103(32). PMID: 16880398    Free PMC article.
Immunosuppressive strategies that are mediated by tumor cells.
Gabriel A Rabinovich, Dmitry Gabrilovich, Eduardo M Sotomayor.
Annu Rev Immunol, 2006 Dec 01; 25. PMID: 17134371    Free PMC article.
Highly Cited. Review.
To ablate or not to ablate? HSCs in the T cell driver's seat.
Claudio Anasetti, James J Mulé.
J Clin Invest, 2007 Feb 03; 117(2). PMID: 17273553    Free PMC article.
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
Li-Xin Wang, Suyu Shu, Mary L Disis, Gregory E Plautz.
Blood, 2007 Feb 08; 109(11). PMID: 17284532    Free PMC article.
A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function.
Gavin M Bendle, Shao-An Xue, Angelika Holler, Hans J Stauss.
PLoS One, 2007 Apr 05; 2(4). PMID: 17406677    Free PMC article.
Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
C Marcela Díaz-Montero, Sabry El Naggar, +4 authors, Mohamed L Salem.
Cancer Immunol Immunother, 2007 Aug 30; 57(4). PMID: 17726606    Free PMC article.
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.
D L DiGiusto, L J N Cooper.
Cytotherapy, 2007 Oct 19; 9(7). PMID: 17943498    Free PMC article.
Review.
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor.
Ryan M Teague, Philip D Greenberg, +6 authors, Claes Ohlén.
Immunity, 2008 Apr 22; 28(5). PMID: 18424189    Free PMC article.
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel, Lionel Apetoh, +3 authors, Guido Kroemer.
J Clin Invest, 2008 Jun 05; 118(6). PMID: 18523649    Free PMC article.
Highly Cited. Review.
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Concetta Quintarelli, Gianpietro Dotti, +7 authors, Barbara Savoldo.
Blood, 2008 Jul 02; 112(5). PMID: 18591381    Free PMC article.
DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire.
Jason Rice, Michelle L Dossett, +5 authors, Philip D Greenberg.
Eur J Immunol, 2008 Jul 16; 38(8). PMID: 18624299    Free PMC article.
Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis.
Jesse Rowley, Archana Monie, Chien-Fu Hung, T-C Wu.
Eur J Immunol, 2009 Jan 31; 39(2). PMID: 19180469    Free PMC article.
Use of tumour-responsive T cells as cancer treatment.
Mary L Disis, Helga Bernhard, Elizabeth M Jaffee.
Lancet, 2009 Feb 24; 373(9664). PMID: 19231634    Free PMC article.
Review.
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.
Joseph F Grosso, Monica V Goldberg, +7 authors, Charles G Drake.
J Immunol, 2009 May 21; 182(11). PMID: 19454660    Free PMC article.
Cellular immunotherapy for ovarian cancer.
Martin J Cannon, Timothy J O'Brien.
Expert Opin Biol Ther, 2009 May 22; 9(6). PMID: 19456205    Free PMC article.
Review.
Betting on immunotherapy for melanoma.
Mario Sznol.
Curr Oncol Rep, 2009 Aug 15; 11(5). PMID: 19679015
Review.
Novel human interleukin-15 agonists.
Xiaoyun Zhu, Warren D Marcus, +6 authors, Hing C Wong.
J Immunol, 2009 Aug 28; 183(6). PMID: 19710453    Free PMC article.
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy.
Yuki Hori, Patrick J Stern, Richard O Hynes, Darrell J Irvine.
Biomaterials, 2009 Sep 22; 30(35). PMID: 19766305    Free PMC article.
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
Scott E James, Nural N Orgun, +5 authors, Oliver W Press.
Blood, 2009 Nov 03; 114(27). PMID: 19880489    Free PMC article.
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.
Malcolm K Brenner, Fatma V Okur.
Hematology Am Soc Hematol Educ Program, 2009 Dec 17;. PMID: 20008253    Free PMC article.
Review.
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Courtney A Crane, Seunggu J Han, +3 authors, Andrew T Parsa.
Neuro Oncol, 2010 Feb 13; 12(1). PMID: 20150362    Free PMC article.
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.
Christian M Capitini, Terry J Fry, Crystal L Mackall.
Am J Immunol, 2010 Feb 26; 5(3). PMID: 20182648    Free PMC article.
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
Theresa L Whiteside.
Expert Opin Biol Ther, 2010 Apr 27; 10(7). PMID: 20415597    Free PMC article.
Review.
Directing dendritic cell immunotherapy towards successful cancer treatment.
Rachel Lubong Sabado, Nina Bhardwaj.
Immunotherapy, 2010 May 18; 2(1). PMID: 20473346    Free PMC article.
Review.
Natural killer cell education and tolerance.
Mark T Orr, Lewis L Lanier.
Cell, 2010 Sep 21; 142(6). PMID: 20850008    Free PMC article.
Highly Cited. Review.
Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.
Ingunn M Stromnes, Joseph N Blattman, +3 authors, Philip D Greenberg.
J Clin Invest, 2010 Oct 05; 120(10). PMID: 20890046    Free PMC article.
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Yangbing Zhao, Edmund Moon, +9 authors, Carl H June.
Cancer Res, 2010 Oct 12; 70(22). PMID: 20926399    Free PMC article.
Highly Cited.
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
Jürgen Kuball, Karin de Boer, +11 authors, Matthias Theobald.
Cancer Immunol Immunother, 2010 Oct 22; 60(2). PMID: 20963411    Free PMC article.
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.
Stephanie K Watkins, Ziqiang Zhu, +6 authors, Arthur A Hurwitz.
J Clin Invest, 2011 Mar 26; 121(4). PMID: 21436588    Free PMC article.
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo.
Nicholas D Huntington, Nuno L Alves, +12 authors, James P Di Santo.
Proc Natl Acad Sci U S A, 2011 Mar 30; 108(15). PMID: 21444793    Free PMC article.
Interleukin-15 enhances T-cell responses by stimulation with dendritic cells.
Yu Zhao, Ke Cheng, +10 authors, Ji-Yan Liu.
Clin Transl Oncol, 2011 Apr 16; 13(4). PMID: 21493189
Selective expansion and enhanced anti-tumor effect of antigen-specific CD4(+) T cells by retrovirus-mediated IL-15 expression.
Jizhou Lv, Ning Tao, +4 authors, Zhihai Qin.
Protein Cell, 2011 Aug 09; 2(7). PMID: 21822803    Free PMC article.
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
Ulrike Gerdemann, Usha Katari, +11 authors, Ann M Leen.
Mol Ther, 2011 Sep 15; 19(12). PMID: 21915103    Free PMC article.
Multiple vaccinations: friend or foe.
Sarah E Church, Shawn M Jensen, +4 authors, Bernard A Fox.
Cancer J, 2011 Sep 29; 17(5). PMID: 21952289    Free PMC article.
Review.
Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.
Andrea Schietinger, Jeffrey J Delrow, +2 authors, Philip D Greenberg.
Science, 2012 Jan 24; 335(6069). PMID: 22267581    Free PMC article.
Highly Cited.
Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
Ingunn M Stromnes, Carla Fowler, +8 authors, Philip D Greenberg.
J Immunol, 2012 Jul 17; 189(4). PMID: 22798667    Free PMC article.
Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.
Jennifer D Stone, Adam S Chervin, Hans Schreiber, David M Kranz.
Biotechnol Prog, 2012 Sep 11; 28(6). PMID: 22961781    Free PMC article.
Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies.
Jeffry Cutrera, Blake Johnson, Lee Ellis, Shulin Li.
Cancer Lett, 2012 Nov 01; 329(1). PMID: 23111105    Free PMC article.
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.
Melissa M Berrien-Elliott, Stephanie R Jackson, +6 authors, Ryan M Teague.
Cancer Res, 2012 Nov 29; 73(2). PMID: 23188506    Free PMC article.
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Carlos A Ramos, Neeharika Narala, +8 authors, Cliona M Rooney.
J Immunother, 2012 Dec 06; 36(1). PMID: 23211628    Free PMC article.
Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.
Carolina Berger, Michael Berger, +3 authors, Stanley R Riddell.
PLoS One, 2013 Feb 19; 8(2). PMID: 23418547    Free PMC article.
Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.
Cary Hsu, John D Abad, Richard A Morgan.
J Surg Res, 2013 Apr 16; 184(1). PMID: 23582229    Free PMC article.
CD40 ligation reverses T cell tolerance in acute myeloid leukemia.
Long Zhang, Xiufen Chen, +4 authors, Justin Kline.
J Clin Invest, 2013 Apr 27; 123(5). PMID: 23619361    Free PMC article.
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner.
Rebecca Berlant Liu, Boris Engels, +4 authors, Bana Jabri.
Proc Natl Acad Sci U S A, 2013 May 03; 110(20). PMID: 23637340    Free PMC article.
Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.
Elena Chertova, Cristina Bergamaschi, +7 authors, George N Pavlakis.
J Biol Chem, 2013 May 08; 288(25). PMID: 23649624    Free PMC article.
Impact of T cell selection methods in the success of clinical adoptive immunotherapy.
Natalia Ramírez, Lorea Beloki, +5 authors, Eduardo Olavarría.
Cell Mol Life Sci, 2013 Oct 01; 71(7). PMID: 24077876
Peripheral T-cell tolerance in hosts with acute myeloid leukemia.
Xiufen Chen, Douglas E Kline, Justin Kline.
Oncoimmunology, 2013 Nov 02; 2(8). PMID: 24179704    Free PMC article.
Tolerance and exhaustion: defining mechanisms of T cell dysfunction.
Andrea Schietinger, Philip D Greenberg.
Trends Immunol, 2013 Nov 12; 35(2). PMID: 24210163    Free PMC article.
Highly Cited. Review.
Harnessing dendritic cells for tumor antigen presentation.
Stefan Nierkens, Edith M Janssen.
Cancers (Basel), 2011 Jan 01; 3(2). PMID: 24212804    Free PMC article.
Re-adapting T cells for cancer therapy: from mouse models to clinical trials.
Ingunn M Stromnes, Thomas M Schmitt, +2 authors, Philip D Greenberg.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329795    Free PMC article.
Review.
T cell avidity and tumor immunity: problems and solutions.
Arthur A Hurwitz, Steven M Cuss, Katherine E Stagliano, Ziqiang Zhu.
Cancer Microenviron, 2013 Dec 21; 7(1-2). PMID: 24357332    Free PMC article.
Intricacies for posttranslational tumor-targeted cytokine gene therapy.
Jeffry Cutrera, Denada Dibra, +2 authors, Shulin Li.
Mediators Inflamm, 2013 Dec 27; 2013. PMID: 24369443    Free PMC article.
Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance.
Stephanie R Jackson, Jinyun Yuan, +4 authors, Ryan M Teague.
J Leukoc Biol, 2014 May 16; 96(3). PMID: 24823810    Free PMC article.
Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.
Jiusheng Deng, Shala Yuan, +4 authors, Jacques Galipeau.
Cancer Res, 2014 Jun 19; 74(15). PMID: 24938765    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Review.
Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma.
Christine Kathryn Zoon, Wen Wan, Laura Graham, Harry D Bear.
Int J Mol Sci, 2015 Apr 24; 16(4). PMID: 25903148    Free PMC article.
Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.
Yi Zhang, Shenghe Tian, +8 authors, Zhaoyang You.
Oncoimmunology, 2015 May 06; 3(10). PMID: 25941586    Free PMC article.
Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein.
Liang Cheng, Xuexiang Du, Lishan Su, Shengdian Wang.
Oncoimmunology, 2015 May 06; 3(11). PMID: 25941592    Free PMC article.
Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Fahmin Basher, Emily K Jeng, Hing Wong, Jennifer Wu.
Oncotarget, 2015 Dec 02; 7(1). PMID: 26625316    Free PMC article.
Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.
Enping Hong, Ilana M Usiskin, +6 authors, Tarek M Fahmy.
J Biol Chem, 2016 Jan 01; 291(17). PMID: 26719339    Free PMC article.
Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure.
Marianna Di Scala, Irene Gil-Fariña, +5 authors, Gloria González-Aseguinolaza.
Oncotarget, 2016 Jul 01; 7(31). PMID: 27356750    Free PMC article.
Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice.
Marianna Di Scala, Itziar Otano, +11 authors, Gloria González-Aseguinolaza.
J Virol, 2016 Jul 22; 90(19). PMID: 27440883    Free PMC article.
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia.
Lei Qin, Donye Dominguez, +7 authors, Bin Zhang.
Oncotarget, 2016 Aug 16; 7(38). PMID: 27517629    Free PMC article.
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.
Heleen H Van Acker, Sébastien Anguille, +5 authors, Viggo F Van Tendeloo.
J Hematol Oncol, 2016 Oct 01; 9(1). PMID: 27686372    Free PMC article.
Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.
Lauryn E Klevorn, Melissa M Berrien-Elliott, +4 authors, Ryan M Teague.
Cancer Immunol Res, 2016 Nov 03; 4(12). PMID: 27803062    Free PMC article.
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.
Lenka V Hurton, Harjeet Singh, +12 authors, Laurence J N Cooper.
Proc Natl Acad Sci U S A, 2016 Nov 17; 113(48). PMID: 27849617    Free PMC article.
Highly Cited.
Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Sinnie Sin Man Ng, Bethany A Nagy, +6 authors, George N Pavlakis.
Clin Cancer Res, 2016 Dec 18; 23(11). PMID: 27986749    Free PMC article.
Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.
Christine K Zoon, Wen Wan, Laura Graham, Harry D Bear.
Int J Mol Sci, 2017 Feb 02; 18(2). PMID: 28146052    Free PMC article.
A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro.
Sheng Chen, Feifei Gu, +6 authors, Li Liu.
J Hematol Oncol, 2017 Mar 02; 10(1). PMID: 28245833    Free PMC article.
Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8+ T Cells with Broad Antitumor Capacity.
Elena Andrada, Rosa Liébana, Isabel Merida.
EBioMedicine, 2017 Apr 26; 19. PMID: 28438506    Free PMC article.
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Mary Philip, Lauren Fairchild, +11 authors, Andrea Schietinger.
Nature, 2017 May 18; 545(7655). PMID: 28514453    Free PMC article.
Highly Cited.
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.
Shannon K Oda, Andrew W Daman, +5 authors, Philip D Greenberg.
Blood, 2017 Oct 19; 130(22). PMID: 29042364    Free PMC article.
Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Vishal Jindal, Ena Arora, Sorab Gupta.
Med Oncol, 2018 May 08; 35(6). PMID: 29730801
Review.
Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.
Thomas A Waldmann, Milos D Miljkovic, Kevin C Conlon.
J Exp Med, 2019 Dec 11; 217(1). PMID: 31821442    Free PMC article.
Review.
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
Darya Alizadeh, Robyn A Wong, +11 authors, Christine E Brown.
Cancer Immunol Res, 2019 Mar 21; 7(5). PMID: 30890531    Free PMC article.
Highly Cited.
CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates.
Douglas E Kline, Brendan W MacNabb, +3 authors, Justin Kline.
J Immunol, 2018 Nov 14; 201(12). PMID: 30420437    Free PMC article.
The deubiquitinase Otub1 controls the activation of CD8+ T cells and NK cells by regulating IL-15-mediated priming.
Xiaofei Zhou, Jiayi Yu, +7 authors, Shao-Cong Sun.
Nat Immunol, 2019 Jun 12; 20(7). PMID: 31182807    Free PMC article.
Lipophilicity of Bacteriochlorin-Based Photosensitizers as a Determinant for PDT Optimization through the Modulation of the Inflammatory Mediators.
Barbara Pucelik, Luis G Arnaut, Janusz M Dąbrowski.
J Clin Med, 2019 Dec 22; 9(1). PMID: 31861531    Free PMC article.
mRNA as novel technology for passive immunotherapy.
Thomas Schlake, Andreas Thess, Moritz Thran, Ingo Jordan.
Cell Mol Life Sci, 2018 Oct 20; 76(2). PMID: 30334070    Free PMC article.
Review.
Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting.
Y-R Yu, P-C Ho.
Clin Exp Immunol, 2019 Mar 16; 197(2). PMID: 30873592    Free PMC article.
Review.
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.
Connor J Dwyer, Hannah M Knochelmann, +7 authors, Chrystal M Paulos.
Front Immunol, 2019 Mar 08; 10. PMID: 30842774    Free PMC article.
Review.
IL-15 in the Combination Immunotherapy of Cancer.
Thomas A Waldmann, Sigrid Dubois, Milos D Miljkovic, Kevin C Conlon.
Front Immunol, 2020 Jun 09; 11. PMID: 32508818    Free PMC article.
Review.
Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.
Vinay V Vyas, Dominic Esposito, +13 authors, Jianwei Zhu.
Biotechnol Prog, 2011 Dec 14; 28(2). PMID: 22162520    Free PMC article.
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Pinar Ataca Atilla, Mary K McKenna, +10 authors, Erden Atilla.
J Immunother Cancer, 2020 Sep 18; 8(2). PMID: 32938629    Free PMC article.
Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.
Simone Nüssing, Joseph A Trapani, Ian A Parish.
Front Immunol, 2020 Oct 20; 11. PMID: 33072137    Free PMC article.
Review.
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.
Xiaohui Wang, Zhiqiang Wu, +3 authors, Weidong Han.
Front Med, 2020 Aug 15; 14(6). PMID: 32794014
Review.
Targeting ubiquitin signaling for cancer immunotherapy.
Xiaofei Zhou, Shao-Cong Sun.
Signal Transduct Target Ther, 2021 Jan 14; 6(1). PMID: 33436547    Free PMC article.
Review.
Decreased levels of circulating cytokines VEGF, TNF-β and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients.
Zuzana Cierna, Bozena Smolkova, +5 authors, Michal Mego.
Sci Rep, 2021 Jan 16; 11(1). PMID: 33446741    Free PMC article.
Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion.
Yi-Ru Yu, Hana Imrichova, +17 authors, Ping-Chih Ho.
Nat Immunol, 2020 Oct 07; 21(12). PMID: 33020660
A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.
Shannon K Oda, Kristin G Anderson, +8 authors, Philip D Greenberg.
J Exp Med, 2020 Aug 30; 217(12). PMID: 32860705    Free PMC article.
A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.
Hong Xu, Ilia N Buhtoiarov, Hongfen Guo, Nai-Kong V Cheung.
Oncoimmunology, 2021 Mar 26; 10(1). PMID: 33763293    Free PMC article.
Cancer therapy in mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen.
Marco Stringhini, Ilaria Spadafora, +4 authors, Dario Neri.
Cancer Immunol Immunother, 2021 Apr 03; 70(11). PMID: 33796916    Free PMC article.
Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C.
Julia Peña-Asensio, Henar Calvo, +3 authors, Juan-Ramón Larrubia.
Cells, 2021 Apr 04; 10(3). PMID: 33802622    Free PMC article.
Review.
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
Gaowei Li, Zongliang Zhang, +10 authors, Liangxue Zhou.
Oncoimmunology, 2021 Oct 02; 10(1). PMID: 34595061    Free PMC article.
Cytotopic (Cyto-) IL-15 as a New Immunotherapy for Prostate Cancer: Recombinant Production in Escherichia coli and Purification.
Ana M Esteves, Efthymia Papaevangelou, +2 authors, Christine Galustian.
Front Mol Biosci, 2021 Nov 16; 8. PMID: 34778376    Free PMC article.
Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.
Annabelle Emery, Sally Moore, James E Turner, John P Campbell.
Front Oncol, 2022 Apr 02; 12. PMID: 35359426    Free PMC article.
Review.
A mathematical model for treatment using chemo-immunotherapy.
Ophir Nave.
Heliyon, 2022 May 07; 8(4). PMID: 35520602    Free PMC article.